RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03225183|
Recruitment Status : Enrolling by invitation
First Posted : July 21, 2017
Last Update Posted : March 22, 2019
The Framingham Heart Study (FHS) was initiated by the U.S Public Health Service in 1948 and turned over to the newly established National Heart Institute in 1951. The FHS is now jointly led by the National Heart, Lung, and Blood Institute and Boston University. The FHS currently studies risk factors, and the genetics of heart and blood vessel disease, and other health conditions in three generations of study participants. Scientists want to use the data collected from this study to do more research. They want to use a technique that determines the sequence of ribonucleic acid (RNA) molecules.
To study genes related to certain diseases and health conditions. These include heart and blood vessel diseases, lung and blood diseases, stroke, memory loss, and cancer.
People in the FHS Third Generation cohort who already attended exam 2.
Researchers will study samples that have already been collected in the FHS. There will be no active examination or burden to participants. During FHS visits, participants gave blood samples. They gave permission for the blood to be used for genetic research. RNA will be generated from the samples. They will be given a new ID separate from any personal data. They will be stored in a secure FHS lab. The samples will be analyzed. Only certified researchers can access them.
No study participants will be contacted in relation to this project.
|Condition or disease|
|Cardiovascular Disease Hypertension|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||1700 participants|
|Official Title:||An RNA Sequencing Study in the Framingham Heart Study Third Generation Cohort Exam 2|
|Estimated Study Start Date :||March 27, 2019|
|Estimated Primary Completion Date :||March 15, 2020|
|Estimated Study Completion Date :||March 15, 2020|
Cohort Exam 2 Participants
We propose to extend the investigation of transcriptomics in FHS Third Generation cohort exam 2 participants.
- To relate transcriptomic variation to CVD and its risk factors (bloodpressure, lipids, glycemia, adiposity, smoking, and alcohol), includingevaluating RNAs as biomarkers of risk and establishing causation viaMendelian randomization [ Time Frame: Observational ]
- To relate complex transcriptomic variation to other blood-based omics [ Time Frame: Observational ]
- To determine the association of genetic sequence variation fromwhole genome sequencing with gene expression via RNA-seq: Identify genetic variants associated with alternative splicing (sQTLS) [ Time Frame: Observational ]
- To determine the association of genetic sequence variation fromwhole genome sequencing with gene expression via RNA-seq: Identify genetic variants associated with expression of protein coding RNAs (eQTLs) [ Time Frame: Observational ]
- To determine the association of genetic sequence variation fromwhole genome sequencing with gene expression via RNA-seq: Identify genetic variants associated with expression of lncRNAs [ Time Frame: Observational ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03225183
|United States, Massachusetts|
|Framingham Heart Study|
|Framingham, Massachusetts, United States, 01702|
|Principal Investigator:||Daniel Levy, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|